ADLUMIZ: Japan's First Drug to Improve Cancer Cachexia Symptoms
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
ADLUMIZ (anamorelin hydrochloride) is Japan's first approved drug for improving cancer cachexia symptoms in patients with non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and colorectal cancer. Cancer cachexia is a complex metabolic syndrome characterized by weight loss, muscle wasting, fatigue, and decreased appetite that affects a significant proportion of cancer patients and negatively impacts their quality of life and treatment outcomes.
ADLUMIZ works as a ghrelin receptor agonist, stimulating appetite and promoting anabolic processes. Its approval in Japan marks a significant milestone in supportive care for cancer patients, offering a dedicated pharmacological option for managing this debilitating condition.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3